Legal & General Group Plc Buys Shares of 122,575 Core Laboratories Inc. $CLB

Legal & General Group Plc purchased a new stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 122,575 shares of the oil and gas company's stock, valued at approximately $1,427,000. Legal & General Group Plc owned 0.27% of Core Laboratories as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CLB. CWM LLC boosted its holdings in shares of Core Laboratories by 36.1% in the fourth quarter. CWM LLC now owns 2,516 shares of the oil and gas company's stock worth $40,000 after buying an additional 668 shares during the last quarter. Platinum Investment Management Ltd. raised its position in Core Laboratories by 3.9% in the third quarter. Platinum Investment Management Ltd. now owns 23,758 shares of the oil and gas company's stock worth $294,000 after acquiring an additional 889 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Core Laboratories by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company's stock worth $207,000 after purchasing an additional 1,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Core Laboratories by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company's stock worth $418,000 after buying an additional 1,170 shares during the period. Finally, Quarry LP lifted its holdings in Core Laboratories by 118.1% during the third quarter. Quarry LP now owns 2,953 shares of the oil and gas company's stock valued at $36,000 after purchasing an additional 1,599 shares in the last quarter. Hedge funds and other institutional investors own 97.81% of the company's stock.

Wall Street Analyst Weigh In

CLB has been the topic of a number of research analyst reports. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Johnson Rice raised shares of Core Laboratories from a "hold" rating to a "buy" rating and set a $21.00 target price on the stock in a report on Thursday, August 13th. Finally, Weiss Ratings raised shares of Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $21.00.

Insider Buying and Selling

In other Core Laboratories news, CEO Lawrence Bruno acquired 5,000 shares of the company's stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $10.78 per share, with a total value of $53,900.00. Following the purchase, the chief executive officer directly owned 262,438 shares of the company's stock, valued at approximately $2,829,081.64. This represents a 1.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.26% of the stock is owned by company insiders.

Core Laboratories Stock Performance

NYSE CLB opened at $12.51 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55. Core Laboratories Inc. has a 1-year low of $9.79 and a 1-year high of $20.36. The business has a 50 day simple moving average of $11.67 and a two-hundred day simple moving average of $13.97. The stock has a market capitalization of $573.96 million, a PE ratio of 22.34, a P/E/G ratio of 2.48 and a beta of 1.08.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $124.61 million for the quarter, compared to analysts' expectations of $126.26 million. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The company's revenue for the quarter was down 4.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.19 EPS. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. On average, research analysts predict that Core Laboratories Inc. will post 0.56 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Monday, August 10th were given a dividend of $0.01 per share. The ex-dividend date was Monday, August 10th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories's dividend payout ratio (DPR) is 7.14%.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company's portfolio spans two primary service lines: reservoir description and production enhancement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source